Satsuma Pharmaceuticals, Inc. STSA
Set alert
1.10 0.00 0.00%
At close · Jun 7
1.10 Day range 1.10
52-week range unavailable
- Open
- 1.11
- Prev close
- 1.10
- Mkt cap
- 36.47M
- Vol
- 1.83M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.10
- High
- 1.10
- Forward P/E
- -1.29
- Beta
- 0.10
- Short ratio
- 0.05
- Inst. own
- 57.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 11, 2023
- 50-d avg
- 0.991336
- 200-d avg
- 2.18
- 1y target
- 2.00
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00 +81.8% upside
Now 1.10
- Target (low)
- 1.00
- Target (mean)
- 2.00
- Target (high)
- 3.00
Recommendation trend
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.27 | -0.32 – -0.22 | -0.52 | +48.1% | 0 | 0.0% | 2 |
| Next quarter | -0.21 | -0.29 – -0.13 | -0.48 | +56.3% | 0 | 0.0% | 2 |
| Current year | -0.95 | -1.15 – -0.75 | -2.19 | +56.6% | 0 | 0.0% | 2 |
| Next year | -0.85 | -1.53 – -0.18 | -0.95 | +10.5% | 4.38M | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 18, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 30, 2023 | Mizuho | Reiterated | — | Neutral |
| Mar 30, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 15, 2022 | Mizuho | Downgrade | Buy | Neutral |
| Nov 15, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 15, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Oct 10, 2022 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Sep 21, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 31, 2022 | Ladenburg Thalmann | Initiated | — | Buy |
| Aug 25, 2022 | JonesTrading | Initiated | — | Buy |
| May 13, 2022 | Mizuho | Maintained | — | Buy |
| Jun 22, 2021 | Mizuho | Upgrade | Neutral | Buy |
| May 12, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Mar 2, 2021 | Credit Suisse | Upgrade | Underperform | Neutral |
| Sep 21, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 11, 2020 | Mizuho | Downgrade | Buy | Neutral |
| Sep 11, 2020 | Credit Suisse | Downgrade | Outperform | Underperform |
| Sep 11, 2020 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 14, 2020 | Credit Suisse | Maintained | — | Outperform |
| Jul 27, 2020 | HC Wainwright & Co. | Initiated | — | Buy |
| Feb 6, 2020 | Mizuho | Initiated | — | Buy |
| Oct 8, 2019 | Credit Suisse | Initiated | — | Outperform |
| Oct 25, 2013 | DA Davidson | Upgrade | Neutral | Buy |
| Oct 7, 2013 | FBR Capital | Downgrade | Outperform | Market Perform |
| Sep 16, 2013 | Sandler O'Neill | Downgrade | Buy | Hold |
| May 14, 2013 | Sterne Agee | Maintained | — | Buy |
| Jan 15, 2013 | Barclays | Initiated | — | Equal-Weight |
| Jan 14, 2013 | Sterne Agee | Initiated | — | Buy |
| Dec 21, 2012 | Compass Point | Initiated | — | Neutral |
| Apr 11, 2012 | Keefe Bruyette & Woods | Initiated | — | Market Perform |